• SENSEX

    {{sensexData[0].price}} (+{{sensexData[0].change}}%)

  • SENSEX

    {{sensexData[0].price}} ({{sensexData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} (+{{niftyData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} ({{niftyData[0].change}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} (+{{mcxData[2].PerChange}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} ({{mcxData[2].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} (+{{mcxData[0].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} ({{mcxData[0].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} (+{{mcxData[1].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} ({{mcxData[1].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} (+{{mcxData[3].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} ({{mcxData[3].PerChange}}%)

Sai Parenteral's Ltd Back
Registered Office:
No.39 5th Flr Lavanya Arcade-,Jayabheri Enclave Gachibowli, Rangareddy - 500032, Telangana, India. Phone : +91 79979 91301   Fax:
Email :
Website :
Initial public offer of up to 10428288 equity shares of face value of Rs. 5 each ("Equity Shares") of Sai Parenteral's Limited ("Company" or "Issuer") for cash at a price of Rs. 392 per equity share (Including a Share Premium of Rs. 387 Per Equity Share) ("Offer Price") aggregating up to Rs. 408.79 Crore comprising a fresh issue of up to 7270408 equity shares of face value of Rs. 5 each aggregating up to Rs. 285 Crore by the company ("Fresh Issue") and an offer for sale of up to 3,157,880 equity shares of face value of Rs. 5 each aggregating up to Rs. 123.79 Crore ("Offered Shares") by investor selling shareholders (such sale, the "Offer For Sale", and together with the fresh issue, the"Offer"). The offer shall constitute [*]% of the post-offer paid up equity share capital of the company. Price Band: Rs. 372 to Rs. 392 per equity share of face value of Rs. 5 each. The floor price 74.40 times the face value of the equity shares and the cap price is 78.40 times the face value of the equity shares. Bids can be made for a minimum of 38 equity shares of face value of Rs. 5 each and in multiples of 38 equity shares of face value of Rs. 5 each thereafter.
Issue
Opens On Closes On
24-Mar-26 27-Mar-26
Money Payable On
Application Allotment
372.00 0.00
Minimum Application for shares in Nos : 38 Further Multiples of : 38
(₹)(Cr.) Lead Managers to the Issue
Project Cost (₹) 0.00 Arihant Capital Markets Limited
Project Financed through Current Offer (₹) 402.47  
Post Issue Equity Share Capital (₹) 23.67  
Issue Price (₹) 372.00  
Projects
Capacity expansion and upgradation of manufacturing facilities
Establishment of a new R&D Centre
Repayment / prepayment of certain outstanding borrowings
Working capital requirements
Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
General corporate purposes
Promoted By
Anil Kumar Karusala
Vijitha Gorrepati
Karusala Aruna
Listing At
BSE
NSE
Registrar to the Issue

Mandatory Dematerialization for Transfer of Securities, w.e.f 5th December 2018. Refer to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08,2018.

Update/Link your Aadhaar Number with your Demat Account by Submitting a photocopy of Aadhaar card along with a request letter/Modification form.

Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment.

Prevent Unauthorized Transactions in your demat account. Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day....... Issued in the interest of investors.

Prevent unauthorized transactions in your trading account ->Update your mobile numbers/email IDs with your stock brokers. Receive information/alerts of your transactions directly from Exchange on your mobile/email at the end of the day.... Issued in the interest of investors.

Filing Complaints on SCORES - Easy & quick.
a. Register on SCORES portal,
b. Provide mandatory details for filing complaints on SCORES like name, PAN, address, mobile number, email ID.
c. Benefits:
   i. Effective communication
   ii. Speedy redressal of the grievances

Investor Awareness regarding the revised guidelines on margin collection

 

Dear Investor,

As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor.

https://www.bseipf.com/investors_education.html

We believe that an educated investor is a protected investor !!!

 

Risk Disclosure on Derivatives

  • out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:
SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.